Genvoya (Cobicistat/Elvitegravir/Emtricitabine/Tenofovir)

Each Genvoya tablet contains 150 mg of elvitegravir (HIV-1 integrase strand transfer inhibitor), 150 mg of cobicistat (CYP3A inhibitor), 200 mg of emtricitabine (HIV-1 nucleoside analog reverse transcriptase inhibitor), and 10 mg of tenofovir alafenamide (HIV-1 nucleoside analog reverse transcriptase inhibitor). Inactive ingredients include croscarmellose sodium, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide, and sodium lauryl sulfate. The tablets are coated with FD and C Blue No. 2/indigo carmine aluminum lake, iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

FDA Boxed Warning: Severe acute worsening of hepatitis B have occurred in patients who are coinfected with HIV-1 and HBV and have stopped taking products containing emtricitabine and/or tenofovir disoproxil fumarate and can occur upon stopping Genvoya. Liver function should be closely monitored and treatment for hepatitis B initiated if needed. Before you begin treatment with Genvoya, you should tell your doctor about:, All the prescription and over-the-counter medications you take, Your allergies, Your medical history and health problems, Your pregnancy or breastfeeding status, Kidney problems can occur with the use of Genvoya. The doctor should monitor the patient's kidney function before and during treatment with Genvoya., Immune system problems can occur with the use of Genvoya., Lactic acidosis and severe liver enlargement with fat in the liver can occur with Genvoya treatment. All the prescription and over-the-counter medications you take, Your allergies, Your medical history and health problems, Your pregnancy or breastfeeding status

The most common side effect associated with Genvoya is nausea. However, this is not the only side effect that can occur with Genvoya. Contact your doctor right away if you develop side effects that bother you or won't go away.